Chiang J. Li, M.D.
Founder, Head of SAB; BIDMC
Catherine Grillot-Courvalin, M.D., Ph.D.
Institut Pasteur, Unite des Agent Anti-bacteriens, Paris, France
Patrice Courvalin, M.D.
Dr. Courvalin is a Professor at the Institut Pasteur where he directs the French National Reference Center for Antibiotics and is the Head of the Antibacterial Agents Unit since 1983. He is an expert in the genetics and biochemistry of antibiotic resistance in bacteria.
Judy Lieberman, M.D., Ph.D.
Dr. Lieberman received a PhD from Rockefeller University and an MD in the Harvard-MIT Program in Health, Science and Technology. She completed a residency and heme-onc fellowship at Tufts-New England Medical Center and a postdoctoral fellowship in immunology at MIT. The Lieberman laboratory at Harvard University was the first to demonstrate in an animal model that RNA interference (RNAi) could be used to protect animals from disease. Her laboratory is actively working to harness RNAi for therapeutic use for HIV and other indications and has developed novel strategies for cell-specific targeting of small interfering RNAs that are effective in vivo.